117 related articles for article (PubMed ID: 10879240)
1. Correlation between histological grade and c-erbB2 oncoprotein overexpression in infiltrating ductal carcinoma of breast.
Looi LM; Cheah PL; Yap SF
Malays J Pathol; 1997 Jun; 19(1):35-9. PubMed ID: 10879240
[TBL] [Abstract][Full Text] [Related]
2. C-erbB-2 oncoprotein amplification in infiltrating ductal carcinoma of breast relates to high histological grade and loss of oestrogen receptor protein.
Looi LM; Cheah PL
Malays J Pathol; 1998 Jun; 20(1):19-23. PubMed ID: 10879259
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical co-expression of c-erbb-2/Neu oncoprotein, altered tumour suppressor (p53) protein, EGF-R and EMA in histological subtypes of infiltrating duct carcinoma of the breast.
Sharma BK; Ray A; Kaur S; Gupta S
Indian J Exp Biol; 1999 Mar; 37(3):223-7. PubMed ID: 10641149
[TBL] [Abstract][Full Text] [Related]
4. [Immunohistochemical study on the expression of c-erbB2 oncoprotein in breast tumors].
Zhang Z; Xu G; Liu S
Zhonghua Zhong Liu Za Zhi; 1997 Jul; 19(4):287-9. PubMed ID: 11038761
[TBL] [Abstract][Full Text] [Related]
5. Relationship between c-erbB-2 oncoprotein, epidermal growth factor receptor, and estrogen receptor expression in patients with ductal breast carcinoma. Association with tumor phenotypes.
Harłoziñska A; Bar JK; Wenderski R; Bebenek M
In Vivo; 1996; 10(2):217-22. PubMed ID: 8744803
[TBL] [Abstract][Full Text] [Related]
6. [Expression of the c-erbB-2 oncoprotein in mammary Paget's disease. Immunohistochemical study by using 3 antibodies].
Edorh A; Parache RM; Migeon C; N'Sossani B; Rihn B
Pathol Biol (Paris); 1995 Sep; 43(7):584-9. PubMed ID: 8570262
[TBL] [Abstract][Full Text] [Related]
7. HMGA1 protein overexpression in human breast carcinomas: correlation with ErbB2 expression.
Chiappetta G; Botti G; Monaco M; Pasquinelli R; Pentimalli F; Di Bonito M; D'Aiuto G; Fedele M; Iuliano R; Palmieri EA; Pierantoni GM; Giancotti V; Fusco A
Clin Cancer Res; 2004 Nov; 10(22):7637-44. PubMed ID: 15569996
[TBL] [Abstract][Full Text] [Related]
8. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer.
Wright C; Angus B; Nicholson S; Sainsbury JR; Cairns J; Gullick WJ; Kelly P; Harris AL; Horne CH
Cancer Res; 1989 Apr; 49(8):2087-90. PubMed ID: 2564806
[TBL] [Abstract][Full Text] [Related]
9. Detection of estrogen receptor in formalin-fixed and paraffin-embedded breast carcinoma: correlation with histological patterns.
Schmitt FC; Andrade LM; de Lucca LA
Rev Paul Med; 1992; 110(4):158-62. PubMed ID: 1341005
[TBL] [Abstract][Full Text] [Related]
10. Distribution of prognostically unfavourable product of c-erbB-2 oncogene and EGF-R in carcinomas of the breast and uterine cervix.
Ray A; Naik SL; Sharma BK
Indian J Physiol Pharmacol; 2002 Oct; 46(4):423-33. PubMed ID: 12683217
[TBL] [Abstract][Full Text] [Related]
11. The expression of products of oncogens c-erbB2 and EGFR and proliferating antigens Ki67 and PCNA in primary invasive ductal cancer of female breast.
Jeziorski A; Blonski JZ; Niewiadomska H
J Exp Clin Cancer Res; 2000 Mar; 19(1):61-7. PubMed ID: 10840938
[TBL] [Abstract][Full Text] [Related]
12. Detection by immunohistochemistry of c-erbB2 oncoprotein in breast carcinomas and benign mammary lesions.
Edorh A; Leroux A; N'sossani B; Parache RM; Rihn B
Cell Mol Biol (Noisy-le-grand); 1999 Sep; 45(6):831-40. PubMed ID: 10541479
[TBL] [Abstract][Full Text] [Related]
13. The correlation of c-erbB-2 oncoprotein and established prognostic factors in human breast cancer.
Sütterlin MW; Haller A; Gassel AM; Peters K; Caffier H; Dietl J
Anticancer Res; 2000; 20(6D):5083-8. PubMed ID: 11326673
[TBL] [Abstract][Full Text] [Related]
14. Long-term survival in breast cancer related to overexpression of the c-erbB-2 oncoprotein: an immunohistochemical study using monoclonal antibody NCL-CB11.
Dykins R; Corbett IP; Henry JA; Wright C; Yuan J; Hennessy C; Lennard TJ; Angus B; Horne CH
J Pathol; 1991 Feb; 163(2):105-10. PubMed ID: 1673154
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome.
Francis G; Beadle G; Thomas S; Mengersen K; Stein S
Pathology; 2006 Oct; 38(5):391-8. PubMed ID: 17008275
[TBL] [Abstract][Full Text] [Related]
16. Adrenocorticotropic hormone and growth factor receptors in breast cancer.
Ray A; Ratnakar N; Murthy NS; Sharma BK
Indian J Exp Biol; 2000 Jul; 38(7):663-8. PubMed ID: 11215308
[TBL] [Abstract][Full Text] [Related]
17. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma.
Couturier J; Vincent-Salomon A; Nicolas A; Beuzeboc P; Mouret E; Zafrani B; Sastre-Garau X
Mod Pathol; 2000 Nov; 13(11):1238-43. PubMed ID: 11106082
[TBL] [Abstract][Full Text] [Related]
18. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation.
Rakha EA; Putti TC; Abd El-Rehim DM; Paish C; Green AR; Powe DG; Lee AH; Robertson JF; Ellis IO
J Pathol; 2006 Mar; 208(4):495-506. PubMed ID: 16429394
[TBL] [Abstract][Full Text] [Related]
19. [Relationship of oncogene C-erbB2 expression to ER, PR and PS2 in breast cancer and its prognostic significance].
Yang JQ; Chen L; Xing TY
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 May; 35(3):334-6, 357. PubMed ID: 15181828
[TBL] [Abstract][Full Text] [Related]
20. The clinicopathological and prognostic significance of membrane type 1 matrix metalloproteinase (MT1-MMP) and MMP-9 according to their localization in invasive breast carcinoma.
Mylona E; Nomikos A; Magkou C; Kamberou M; Papassideri I; Keramopoulos A; Nakopoulou L
Histopathology; 2007 Feb; 50(3):338-47. PubMed ID: 17257129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
